Raymond James Financial Services Advisors, Inc. Chemo Centryx, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$22.17 - $51.8 $3.85 Million - $9 Million	-173,781 Reduced 66.96%	85,738 $4.43 Million
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $189,649 - $339,665	12,347 Added 5.0%	259,519 $6.43 Million
Q1 2022 May 11, 2022	SELL	$22.22 - $39.12 $264,973 - $466,505	-11,925 Reduced 4.6%	247,172 $6.2 Million
Q4 2021 Feb 08, 2022	SELL	$18.38 - $40.5 $2.26 Million - $4.97 Million	-122,763 Reduced 32.15%	259,097 $9.43 Million
Q3 2021 Nov 02, 2021	BUY	$13.18 - $19.83 $858,782 - $1.29 Million	65,158 Added 20.57%	381,860 $6.53 Million
Q2 2021 Aug 11, 2021	BUY	$9.59 - $50.88 $785,449 - $4.17 Million	81,903 Added 34.88%	316,702 $4.24 Million
Q1 2021 May 14, 2021	BUY	$49.53 - $68.4 $1.72 Million - $2.37 Million	34,694 Added 17.34%	234,799 $12 Million
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $6.75 Million - $9.31 Million	142,812 Added 249.27%	200,105 $12.4 Million
Q3 2020 Nov 04, 2020	SELL	$46.35 - $61.69 $249,687 - $332,324	-5,387 Reduced 8.59%	57,293 $3.14 Million
Q2 2020 Jul 17, 2020	BUY	$38.58 - $65.07 $934,870 - $1.58 Million	24,232 Added 63.03%	62,680 $3.61 Million
Q1 2020 Apr 21, 2020	BUY	$32.73 - $50.78 $1.03 Million - $1.6 Million	31,498 Added 453.21%	38,448 $1.55 Million
Q4 2019 Feb 12, 2020	BUY	$6.81 - $39.55 $47,329 - $274,872	6,950 New	6,950 $275,000

Others Institutions Holding CCXI

# of Institutions

Shares Held

66.3K

Call Options Held

Put Options Held

View Full List

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account